Key Performance
More- Earnings Score: N/A
- Momentum Score: 24
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Serina Therapeutics announced that its Chief Development Officer will present data on novel POZ-based lipid nanoparticles (LNPs) that overcome PEG immunogenicity issues. The company's POZ-lipid showed no antibody response in rat vaccine studies, unlike standard PEG-lipids which elicit immune responses. Serina is also advancing replacement ionizable lipids to address safety concerns in LNP formulations.
04/07/2026, 6:00 AM • GlobeNewswire
Serina Therapeutics to Present at the 38th Annual Roth Conference
Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platform™ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphine) for Parkinson's disease and has secured partnerships including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery applications.
03/24/2026, 6:00 AM • GlobeNewswire
U.S. stock futures declined on Friday with major indices down slightly ahead of 'triple witching' expiration. FedEx surged 10.43% on better-than-expected earnings and raised guidance, while Super Micro Computer plunged 23.61% after its co-founder was charged in an alleged AI technology export scheme to China. Planet Labs soared 17.25% and Scholastic gained 10.54% on strong earnings. Geopolitical tensions with Iran and energy market disruptions added to market uncertainty.
03/20/2026, 8:51 AM • Benzinga
Serina Therapeutics announced the first patient enrollment in its Phase 1b registrational trial of SER-252, an investigational apomorphine therapy for advanced Parkinson's disease. The trial, initiated in Australia, evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy. The company remains on track for first patient dosing in Q1 2026 and has FDA alignment on its 505(b)(2) NDA registrational pathway.
02/19/2026, 6:00 AM • GlobeNewswire
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
Serina Therapeutics' CEO Steven Ledger will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives and their impact on drug development. The company recently received FDA clearance for its SER-252 IND application for Parkinson's disease treatment and is initiating Phase 1b clinical activities in Australia.
02/03/2026, 6:00 AM • GlobeNewswire
Serina Therapeutics introduces a comprehensive communications platform to provide transparent updates about its SER-252 Parkinson's disease trial, focusing on patient, clinician, and investor engagement.
10/08/2025, 11:00 AM • GlobeNewswire
Pet's Best Life received the 'Overall Dog Health Product of the Year' award for Longevity15®, a supplement containing C15:0 that supports cellular health and longevity in dogs, developed in partnership with Seraphina Therapeutics.
08/13/2025, 11:00 AM • GlobeNewswire
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
Serina Therapeutics is developing a drug candidate, SER-252, designed to provide continuous dopaminergic stimulation for better symptom control in Parkinson's disease. The company's proprietary POZ Platform technology aims to improve the safety, duration, and tolerability of Parkinson's treatments.
06/23/2025, 7:24 PM • GlobeNewswire
